Research and Clinical Trials

Title  

COG AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Brief Description  

To compare EFS in patients with newly diagnosed T-ALL and T-LLy who are randomized to a modified ABFM backbone versus bortezomib plus the modified ABFM backbone. The primary goal in this trial is to prevent relapse. AALL1231 will test two major strategies to meet this goal: (1) to modify the existing chemotherapy platform to mirror the most efficacious backbone that has been tested in Phase 3 trials; and, (2) to randomize patients to receive/not receive a novel agent (bortezomib), with strong b

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Leukemia, not otherwise specified

Status  

OPEN

Start Date  

05/17/2015

IRB Number  

00010588

Principal Investigator  

Kaplan, Joel Adam

Contact Name  

Sceria Jenkins

For More Information, Contact  Sceria  , Jenkins
Phone:  980-442-2323 Fax:    
Email:  sceria.jenkins@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204